Delivery Order SPE2DB20D1051-SPE2DB25FD8WE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a ceiling value of $12,700.91. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award falls under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for Dupixent 300mg/2ml syringes valued at $44,390.30. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 20, 2025, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The award does not utilize a set-aside designation and represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $1,709.46. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 10, 2025, to be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $4,791.86 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dupixent 300 mg/2 ml syringes (2 ml volume). The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical products will be delivered to the contractor's location in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a contract ceiling value of $58,540.83. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was made on a competitive, non-set-aside basis, with performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a ceiling value of $3,418.92 under a firm fixed-price contract. This award represents a non-set-aside competitive procurement and is a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at the company's corporate office location in...
- The Defense Logistics Agency awarded a $47,704.56 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 8, 2025, and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL syringes valued at $4,991.39. This non-set-aside, firm fixed-price delivery order is scheduled for completion by July 28, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a discrete purchase under AmerisourceBergen's existing contract vehicle with the DLA. AmerisourceBergen Drug Corp is a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,957.42 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This non-competitive delivery order, with a firm fixed price structure, represents a child contract against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $8,571.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Dupixent 300 mg/2 ml syringes. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The product will be delivered to the company's corporate office location...
- SPE2DB20D1051Indefinite Delivery Contract
- SPE2DB20D1051-SPE2DB25FD8WEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $3,577.74. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement. The award will be fulfilled from the vendor's place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is a child contract under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal vendor for the Defense Logistics Agency's Medical Supply Chain, supplying brand-name and generic medications, vaccines, and specialized medical supplies to support military and veteran healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to meet competitive procurement requirements across multiple therapeutic domains. This specific delivery order for Dupixent, a specialty pharmaceutical product, reflects the company's ongoing role in supplying specialized medications through the DLA's comprehensive pharmaceutical support vehicle for global military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 7/22/25 |